Australia's largest stock trading and investment forum Australia's #1 stock forum

IMU imugene limited

18.2%

1.3¢

Safety is the expectation for Ph1 clinical trial and any...

First 17079 Last

Share
Profile

Follow
AlCp

30,694 Posts.

2030

11/01/25

19:01

Post #: 77364324
Share

Originally posted by Devildamian ↑

Yep. Because the dance card is full and ole mate is on the phone all day negotiating bigger and better deals.
Oh nope wait. His position became redundant.
first cf33 trial completion in june. Table of results put up on video few months back.
result as of june on the bottom.
" cf33 is performing as expected after clinical trials"
What were their expectations???? 1 cr out of 38?
Pretty sure I remember them stating they were at about optimal dose levels too at one stage.

Expand

Safety is the expectation for Ph1 clinical trial and any efficacy seen has exceed expectation as this is usually seen in Ph2 clinical trial, LC has mentioned the purpose of Ph1 clinical trial even in the ASX announcement.

IMU Price at posting: 4.3¢ Sentiment: None Disclosure: Held
6 Upvote

0 Great analysis

Reply

Top Stories

'Not possible' to port renewable gas: ACCC takes AGN to court

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

BOE

Boss extends June win streak with boosted Alta Mesa extraction rates

SRL

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

PAR

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

OCC

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

ASX Market Open: IPO hype, Wall Street ATHs push Aussies into green hope | June 27

First 17079 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 1.3¢		Change 0.002(18.2%)		Mkt cap ! $97.07M

Open	High	Low	Value	Volume
1.2¢	1.4¢	1.1¢	$625.7K	50.56M

Buyers (Bids)

No.	Vol.	Price($)
20	5795292	1.2¢

Sellers (Offers)

Price($)	Vol.	No.
1.3¢	3258567	9

View Market Depth

No.	Vol.	Price($)
20	5795292	0.012
39	12054746	0.011
123	37475571	0.010
38	20531668	0.009
14	4320747	0.008

Price($)	Vol.	No.
0.013	3258567	9
0.014	11336079	44
0.015	6830166	21
0.016	6274494	28
0.017	7081669	12

Last trade - 16.10pm 27/06/2025 (20 minute delay)

IMU (ASX) Chart

Safety is the expectation for Ph1 clinical trial and any...

'Not possible' to port renewable gas: ACCC takes AGN to court

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Boss extends June win streak with boosted Alta Mesa extraction rates

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

Australia’s gas crisis is here – and dying coal plants aren’t helping

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

ASX Market Open: IPO hype, Wall Street ATHs push Aussies into green hope | June 27

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Safety is the expectation for Ph1 clinical trial and any...

Top Stories

'Not possible' to port renewable gas: ACCC takes AGN to court

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Boss extends June win streak with boosted Alta Mesa extraction rates

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

Australia’s gas crisis is here – and dying coal plants aren’t helping

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

ASX Market Open: IPO hype, Wall Street ATHs push Aussies into green hope | June 27

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News